Lung Function Profiles among Individuals with Nonmalignant Asbestos-related Disorders

Eun-Kee Park 1,*, Deborah H. Yates 2, Donald Wilson 3

1 Department of Medical Humanities and Social Medicine, College of Medicine, Kosin University, Busan, Korea
2 Department of Thoracic Medicine, St Vincent’s Hospital, Sydney, NSW, Australia
3 Department of Occupational Toxicology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan

A R T I C L E   I N F O

Article history:
Received 28 April 2014
Received in revised form
30 July 2014
Accepted 31 July 2014
Available online 7 August 2014

Keywords:
asbestos
asbestosis
diffuse pleural thickening
pleural plaques
lung function

A B S T R A C T

Background: Inhalation of asbestos fibers can lead to adverse health effects on the lungs. This study describes lung function profiles among individuals with nonmalignant asbestos-related disorders (ARDs).

Methods: The study population was from the Workers’ Compensation (Dust Diseases) Board of New South Wales, Sydney, Australia. Lung function measurements were conducted in males with asbestosis (n = 26), diffuse pleural thickening (DPT; n = 129), asbestosis and DPT (n = 14), pleural plaques only (n = 160) and also apparently healthy individuals with a history of asbestos exposure (n = 248). Standardized spirometric and single-breath diffusing capacity for carbon monoxide (Dlco) measurements were used.

Results: Mean age [standard deviation (SD)] was 66.7 (10.3) years for all participants. Current and ex-smokers among all participants comprised about 9.0% and 54.8%, respectively. Median pack-years (SD) of smoking for ex- and current-smokers were 22.7 (19.9). Overall 222 participants (38.6%) and 139 participants (24.2%) had forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) measurements < 80% predicted, and 217 participants (37.7%) had FEV1/FVC results < 70%. A total of 249 individuals (43.8%) had DLco values < 80% predicted and only 75 (13.2%) had DLco/VA results < 80% predicted. A total of 147 participants (25.6%) had peak expiratory flow (PEF) measurements < 80% predicted. The presence of ARDs lowered the lung function measurements compared to those of healthy individuals exposed to asbestos.

Conclusion: Lung function measurement differs in individuals with different ARDs. Monitoring of lung function among asbestos-exposed populations is a simple means of facilitating earlier interventions.

Copyright © 2014, Occupational Safety and Health Research Institute. Published by Elsevier. All rights reserved.

1. Introduction

Asbestos is a naturally occurring mineral fiber which is known as a human carcinogen [1]. More than 100,000 people die annually in occupational settings due to asbestos-related diseases caused by inhalation of asbestos fibers [2]. Diseases related to asbestos exposure mostly affect the respiratory system, but in rare cases they affect other locations such as the ovaries and larynx [1]. Reduced lung function among individuals with a history of asbestos exposure is common and has been well recognized [3–6]. Although substantial evidence for impairment of lung function is already described in populations exposed to asbestos, many studies have included cohorts of asbestos-exposed workers, with fewer comparisons between asbestos-exposed individuals without disease and those with asbestos-related disorders (ARDs). The use of lung function measurements to screen ARDs is still widely employed as a primary screening tool.

Several recent reports have warned that ARDs in Asian countries could increase in the near future [7–9] because asbestos consumption has been high since the late 1980s and into the 1990s [10].

* Corresponding author. Department of Medical Humanities and Social Medicine, College of Medicine, Kosin University, 262 Gamcheonro, Seogu, Busan 602-702, Korea.
E-mail address: ekpark@kosin.ac.kr (E.-K. Park).

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

2093-7911/$ – see front matter © 2014, Occupational Safety and Health Research Institute. Published by Elsevier. All rights reserved.
http://dx.doi.org/10.1016/j.shaw.2014.07.007
Caution is necessary in ensuring that an accurate diagnosis of ARD is made prior to monitoring of lung function. Nevertheless, adverse health impacts from asbestos exposure are not well recognized in this region. The purpose of this study was to determine the lung function profiles among individuals with nonmalignant ARDs.

2. Materials and methods

2.1. Study population

We obtained data from a study population that is well-described elsewhere [11]. In brief, the study was conducted at the Workers’ Compensation (Dust Diseases) Board of New South Wales, Sydney, Australia. This study had approval from the Human Research Ethics Committee of St. Vincent’s Hospital, Sydney, Australia. All participants gave their written informed consent and were not compensated for their participation. Participants were diagnosed with their respective ARDs according to the American Thoracic Society (ATS) criteria [12]. Criteria for asbestosis included a history 25 fiber/mL-years exposure to asbestos, the presence of bilateral fine end-inspiratory crackles on auscultation, and the presence of subpleural interstitial opacities on chest radiology (usually high resolution computer tomography scan), in the absence of other causes of interstitial pulmonary fibrosis. Criteria for the diagnosis of diffuse pleural thickening (DPT) were involvement of ≥25% of the chest wall on plain chest radiology, 8 cm × 5 cm × 3 cm in total on chest computer tomography, and/or the presence of Blesovsky’s syndrome [13]. Pleural plaques were diagnosed according to their presence on chest radiograph or computer tomography scan, and included calcified and non-calcified circumscribed pleural thickening.

In New South Wales, compensation for ARDs is provided by the Dust Diseases Board (DDB) according to the Workers’ Compensation (Dust Diseases) Act 1942. Individuals with known or suspected “dust diseases” are referred to the DDB and undergo a standardized occupational history documenting asbestos exposure, clinical examination, lung function testing, and medical imaging as required. Information is then reviewed by a Medical Authority consisting of at least three appropriately qualified thoracic physicians. A diagnosis is reached or declined, and an assessment of disablement made according to American Medical Association IV criteria [14].

2.2. Pulmonary function assessment

Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), percent ratio between FEV1 and FVC (FEV1/FVC), single-breath carbon monoxide diffusing capacity (DLco) and DLco/alveolar volume (DLco/VA), and peak expiratory flow (PEF) were measured by spirometry using the Sensormedics Vmax 22D-Spectra (Viasys Healthcare, Conshohocken, PA, USA). During the study period, the same equipment was used by the same trained technician. At least three FVC manoeuvres and DLco trials were obtained for each participant according to ATS guidelines [15,16]. The results were expressed as absolute values and as percent of the predicted values for FVC, FEV1, and DLco calculated on the basis of age, height, and gender for Caucasians, using the predictive equations provided by the European Respiratory Society 1993 update [17].

2.3. Data analysis

Descriptive statistics were performed for outcome and predictor variables and covariates. Analysis of variance test and generalized linear models (GLM) were used to compare means, while adjusting for confounding factors, namely age, smoking pack-years, and body mass index (BMI). The GLM procedure uses the method of least squares and analyzes data within the framework of general linear models, and in this case, we use the models not only to compare two or more means, but also as linear regressions, to predict the effect of a factor on an outcome variable. All comparisons were two-sided and p < 0.05 was treated as significant. Analyses were performed in SAS, version 10 (SAS Institute Inc., Cary, NC, USA).

3. Results

3.1. Study population

Baseline characteristics of the participants in this study are shown in Table 1. Data analyzed from the 577 males comprised the following categories: asbestosis (n = 26), DPT (n = 129), asbestosis and DPT (n = 14), pleural plaques only (n = 160, PPs) and apparently healthy individuals formerly exposed to asbestos (n = 248). Mean age (SD) was 66.7 (10.3) years for all participants. Current and ex-smokers among all participants comprised about 9.0% and 54.8%, respectively. Median pack-years (SD) of smoking for current and ex-smokers were 22.7 (19.9). A total of 469 participants (81.3%) were overweight and obese (BMI ≥ 25).

3.2. Pulmonary function measures

Pulmonary function outcome measures are described in Table 2. Out of the sample population, 222 participants (38.6%) and 139 participants (24.2%) had FEV1 and FVC measures that were <80% predicted, respectively, and 217 participants (37.7%) had FEV1/FVC <80% predicted, respectively. FEV1 predicted, respectively, and 217 participants (37.7%) had FEV1/FVC <80% predicted.

Table 1: Characteristics of participants by asbestos-related disorder category

| Characteristic | All [n (%)] | Healthy  | Asbestosis | DPT | Asbestosis/DPT | Pleural plaques | p   |
|----------------|-------------|----------|------------|-----|----------------|-----------------|-----|
| Subjects included in final analysis | 577 (100)   | 248 (43.0) | 26 (4.5) | 129 (22.4) | 14 (2.4) | 160 (27.7) | 0.0001 |
| Age [Mean (SD)] [y] | 66.7 (10.3) | 60.9 (10.5) | 72.7 (6.7) | 71.8 (6.8) | 72.9 (6.7) | 69.3 (8.9) | 0.0001 |
| Smoking status (%) | 54.8 | 42.3 | 61.5 | 73.6 | 85.7 | 55.0 | 0.0001 |
| Ex-smoker | 36.2 | 46.0 | 26.9 | 20.9 | 14.3 | 36.9 | 0.0076 |
| Current smoker | 22.7 (19.9) | 210 (18.2) | 24.8 (14.4) | 23.5 (18.8) | 15.9 (18.0) | 24.5 (23.7) | 0.0027 |
| Pack years [mean (SD)] | 150 (18.2) | 46 (18.6) | 3 (11.5) | 17 (12.2) | 2 (14.2) | 37 (23.1) | 0.2027 |
| Body mass index, kg/m² [n (%)] | 88.5–24.9 | 250–29.9 | 30–3 | 0.2027 |
| Antioxidation | 105 (18.2) | 117 (47.2) | 17 (65.4) | 69 (53.5) | 10 (71.4) | 81 (50.6) | 0.2027 |
| <30 | 175 (30.3) | 83 (33.5) | 6 (23.1) | 43 (33.1) | 2 (14.3) | 41 (25.6) | 0.2027 |

ANOVA: analysis of variance.

* Apparently healthy with a history of asbestos exposure.

† Diffuse pleural thickening.

‡ For significance testing: Chi-square tests were performed for proportions and ANOVA analyses for arithmetic means.
results that were <70% predicted. A total of 249 participants (43.8%) had DLco values <80% predicted and only 75 participants (13.2%) had DLco/VA results <80% predicted. A total of 147 participants (25.6%) had PEF measures of <80% predicted (Table 2). Mean (SD) FEV₁% predicted levels in individuals with asbestosis [78.4 (14.0%)] and PPs [85.9 (18.4%)] were significantly lower than the apparently healthy individuals formerly exposed to asbestos [92.5 (17.2%)] (p < 0.0001). Mean (SD) FVC% predicted levels in individuals with asbestosis [81.9 (15.8%)] and DPT [79.4 (16.0%)] were significantly lower than the apparently healthy individuals with a history of asbestos exposure [100.2 (14.6%)] (p < 0.0001). Mean (SD) DLco% predicted levels in participants with asbestosis [59.6 (14.1%)] and PPs [94.7 (14.9%)] were significantly lower than the apparently healthy individuals with a history of asbestos exposure [100.2 (14.6%)] (p < 0.0001). Comparison of spirometry and diffusion capacity outcomes between the healthy individuals and individuals with ARDs revealed statistically significant differences in mean percent predicted for all of these parameters (Table 2).

Age, smoking pack-years, and BMI were included in GLM models to adjust for their effects on the lung function profiles of the healthy and ARD groups (Table 2) which was similar to the unadjusted profiles reported in Table 2. The apparently healthy participants with a history of asbestos exposure had better lung function than those with ARDs, and differences across all groups were statistically significant (p < 0.0001, Table 3). Interestingly, when compared to the unadjusted lung function profiles, controlling for the effects of these three independent variables results in an overall reduction in the lung function only among the healthy participants. The unadjusted mean (SD) of FEV₁, FVC, FEV₁/FVC, DLco, DLco/VA, and PEF predicted values in the healthy group were 92.5 (17.2), 72.6 (8.7), 90.6 (18.9), and 100.5 (20.3), respectively. However, whereas the adjusted mean (SD) of FEV₁, FVC, FEV₁/FVC, DLco, DLco/VA, and PEF predicted values in the healthy group were 90.4 (15.6), 98.1 (12.1), 70.8 (10.2), 87.6 (16.2), 101.9 (16.8), and 98.2 (18.4), respectively. Of the six lung function measures, the lowest mean values recorded were evenly distributed among the participants with asbestosis, DPT, and asbestosis/DPT.

4. Discussion

Although the best way of elimination of ARDs is simply to ban asbestos usage, new cases of mesothelioma, the worst health effect of asbestos exposure, continue to rise worldwide, due to the long latency period between exposure and disease development. Effective screening of ARDs is essential for the better management of ARDs. Asbestos exposure is mostly associated with lung function impairments [3–6]. Lung function has also been proven to be the best predictor of survival of asbestos exposure workers.

The current study found significant differences between ARDs across all lung function measures, in agreement with previous studies. The presence of pleural plaques has been significantly associated with respiratory impairment in some studies [21], but not in others. Male asbestos-exposed individuals with DPT showed lower DLco and FVC than individuals without a history of asbestos exposure alone, but the FEV₁ and FVC values were not different [22]. In a study from India, workers exposed to asbestos had a mean FVC <80% of the predicted value [23]. Abejie and colleagues [24] found chrysotile exposed workers in China had significantly reduced FVC, FEV₁, FEV₁/FVC, and DLco, and workers with asbestosis had lower FVC and DLco values but not FEV₁/FVC values, compared to workers

---

**Table 2**

| Lung function measures | All | Healthy | Asbestosis | DPT | Asbestosis/DPT | Pleural plaques | p |
|------------------------|-----|---------|------------|-----|--------------|----------------|---|
| FEV₁                   | 84.3 (19.4) | 92.5 (17.2) | 78.4 (14.0) | 69.5 (16.4) | 68.6 (11.7) | 85.9 (18.4) | <0.0001 |
| FVC                    | 92.5 (17.5) | 100.2 (14.6) | 81.9 (15.8) | 79.4 (16.0) | 71.4 (13.2) | 94.7 (14.9) | <0.0001 |
| FEV₁/FVC               | 70.7 (10.0) | 72.6 (8.7) | 73.6 (9.3) | 67.2 (10.8) | 73.9 (10.1) | 69.8 (10.5) | <0.0001 |
| DLco                   | 82.6 (20.0) | 90.6 (18.9) | 59.6 (14.1) | 72.7 (16.6) | 62.2 (17.8) | 83.6 (17.7) | <0.0001 |
| DLco/VA                | 102.5 (20.5) | 103.2 (18.6) | 90.4 (23.6) | 104.2 (22.5) | 98.0 (25.2) | 102.2 (20.4) | 0.031 |
| PEF                    | 93.6 (22.0) | 100.5 (20.3) | 94.1 (19.9) | 80.8 (21.7) | 80.4 (19.3) | 94.4 (20.4) | <0.0001 |

ANOVA, analysis of variance; DLco, diffusing capacity for carbon monoxide; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow; SD, standard deviation.

Data are presented as mean (SD).

ANOVA, analysis of variance; DLco, diffusing capacity for carbon monoxide; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow; SD, standard deviation.

Data are presented as mean (SD).
with asbestos exposure but without asbestosis. A similar finding in China was also reported by Wang et al. [25], who reported a significant drop in FVC and DLCO in 248 workers exposed to mainly chrysotile.

Our findings support previous data that lung function in individuals with ARDs is significantly lower than currently healthy asbestos-exposed individuals. In our study, important factors which affect lung function such as smoking history, age, and BMI were adjusted for [26,27], but interestingly, controlling for the effects of these three independent variables did not have a large effect on lung function in those with ARDs, only on those who were apparently healthy, possibly due to confounding by severity. It has been known that cumulative exposure of asbestos is strongly associated with lung function decline [28]. The lack of exposure assessment was a limitation in the study, but unfortunately the data was not collected.

In conclusion, occupational and/or environmental exposure to asbestos is strongly related to an increased decline in lung function. Our study shows significant differences in lung function in individuals with ARDs compared to currently healthy individuals with a history of previous exposure to asbestos. Regular monitoring of lung function among asbestos-exposed populations is a simple tool to facilitate earlier interventions.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Acknowledgments

The authors are grateful to all individuals whose participation enabled us to complete the study. This study was supported by a research grant from the Workers’ Compensation (Dust Diseases) Board of New South Wales, Australia and by a grant of the Kosin University College of Medicine, Busan, Republic of Korea.

References

[1] IARC monographs on the evaluation of carcinogenic risks to humans. Volume 100C [Internet]. Lyon (France): International Agency for Research on Cancer. 2012 [cited 2014 Apr 15]. Available from: http://monographs.iarc.fr/ENG/Monographs/vol100C/index.php.
[2] Asbestos: elimination of asbestos-related diseases. Fact sheet No. 343 [Internet]. Geneva (Switzerland): World Health Organization. 2010 [cited 2014 Apr 8]. Available from: http://www.who.int/mediacentre/factsheets/fs343/en/.
[3] Murphy RL, Ferris BG, Burgess WA, Worcester J, Gaensler EA. Effects of low concentrations of asbestos. Clinical, environmental, radiologic and epidemiologic observations in shipyard pipe coverers and controls. N Engl J Med 1971;285:1271–8.
[4] Nakadate T. Decline in annual lung function in workers exposed to asbestos with and without pre-existing fibrotic changes on chest radiography. Occup Environ Med 1995;52:368–73.
[5] Wang XR, Yano E, Nonaka K, Wang M, Wang Z. Pulmonary function of non-smoking female asbestos workers without radiographic signs of asbestosis. Arch Environ Health 1998;53:292–8.
[6] Tonioy Y, Nitsuaya M, Sato T, Sugiyura Y, Miyake H, Aizawa Y. Relationship between chest X-ray findings and pulmonary function tests in dust workers. Ind Health 2005;43:256–66.
[7] Bianchi C, Bianchi T. Malignant mesothelioma in Eastern Asia. Asian Pac J Cancer Prev 2012;13:8489–53.
[8] Le GV, Takahashi K, Park EK, Delgermaa V, Oak C, Qureshi AM, Aljunid SM. Asbestos use and asbestos-related diseases in Asia: past, present and future. Respirology 2011;16:767–75.
[9] Lin S, Wang X, Yu IT, Yano E, Courtice M, Qiu H, Wang M. Cause-specific mortality in relation to chrysotile-asbestos exposure in a Chinese cohort. J Thorac Oncol 2013;7:1109–14.
[10] Le GV, Takahashi K, Karjalainen A, Delgermaa V, Hoshuyama T, Miyamura Y, Furuya S, Higashi T, Pan G, Wagner G. National use of asbestos in relation to economic development: Environ Health Perspect 2010;118:116–9.
[11] Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, Johnson AR. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008;178:832–7.
[12] American Thoracic Society. Diagnosis and initial management of non-malignant diseases related to asbestos. Am J Respir Crit Care Med 2004;170:691–715.
[13] Miles SE, Sandrini A, Johnson AR, Yates DH. Clinical consequences of asbestos-related diffuse pleural thickening: a review. J Occup Med Toxicol 2008;3:20.
[14] Cocchiarella L, Anderson GBJ. Guides to the evaluation of permanent impairment. 5th ed. Chicago (IL): American Medical Association Press; 2001. 350 p.
[15] American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995a;152:1107–36.
[16] American Thoracic Society. Single breath carbon monoxide diffusion capacity (transfer factor), recommendations for a standard technique, 1995 update. Am J Respir Crit Care Med 1995b;152:2185–98.
[17] Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC. Standardization of the measurement of transfer factor (diffusing capacity), report working party standardization of lung function tests, European Community for steel and coal: official statement of the European Respiratory Society. Eur Respir J 1993;6(Suppl. 16):41–53.
[18] Elimination of asbestos-related diseases. WHO/SDE/OEH/06.03 [Internet]. Geneva (Switzerland): World Health Organization. September 2006 [cited 2014 Apr 7]. Available from: http://www.who.int/occupational_health/publications/asbestosrelateddiseases.pdf.
[19] Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011;89:716–24. 724A–724C.
[20] Moshammer H, Neuberger M. Lung function predicts survival in a cohort of asbestos-exposed workers. Occup Environ Med 2013;70:15.
[21] Murlidhar V, Kanhere V. Asbestosis in an asbestos composite mill at Mumbai: a prevalence study. Environ Health 2005;4:24.
[22] Abejie BA, Wang X, Kales SN, Christiani DC. Patterns of pulmonary dysfunction in asbestos workers: a cross-sectional study. J Occup Med Toxicol 2010;5:12.
[23] Wang X, Yano E, Novak K, Wang M, Wang Z. Respiratory impairments due to asbestos, and coalmine dust. Am J Ind Med 1997;31:495–502.
[24] Wang X, Yano E, Wang Z, Wang M, Christiani DC. Adverse effects of asbestos exposure and smoking on lung function. Am J Ind Med 2006;49:337–49.
[25] Algranti E, Mendonca EM, Hnizdo E, De Capitani EM, Freitas JB, Raile V, Bussacos MA. Longitudinal decline in lung function in former asbestos exposed workers. Occup Environ Med 2013;70:15–21.
[26] D1 Wilken, Velasco Garrido M, Manuwal U, Baur X. Lung function in asbestos-exposed workers, a systematic review and meta-analysis. J Occup Med Toxicol 2011;6:23.